In Silico Design and Immunologic Evaluation of HIV-1 p24-Nef Fusion Protein to Approach a Therapeutic Vaccine Candidate

Background: Acquired immune deficiency syndrome (HIV/AIDS) has been a major glob-al health concern for over 38 years. No safe and effective preventive or therapeutic vaccine has been developed although many products have been investigated. Computational methods have facilitated vaccine developments in recent decades. Among HIV-1 proteins, p24 and Nef are two suitable targets to provoke the cellular immune response. However, the fusion form of these two proteins has not been analyzed in silico yet. Objective: This study aimed at the evaluation of possible fusion forms of p24 and Nef in order to achieve a potential therapeutic subunit vaccine against HIV-1. Method: In this study, various computational approaches have been applied to predict the most effec-tive fusion form of p24-Nef including CTL (Cytotoxic T lymphocytes) response, immunogenicity, conservation and population coverage. Moreover, binding to MHC (Major histocompatibility com-plex) molecules was assessed in both human and BALB/c. Results: After analyzing six possible fusion protein forms using AAY linker, we came up with the most practical form of p24 from 80 to 231 and Nef from 120 to 150 regions (according to their refer-ence sequence of HXB2 strain) using an AAY linker, based on their peptides affinity to MHC mole-cules which are located in a conserved region among different virus clades. The selected fusion protein contains seventeen MHC I antigenic epitopes, among them KRWIILGLN, YKRWIILGL, DIAG-TTSTL and FPDWQNYTP are fully conserved between the virus clades. Furthermore, analyzed class I CTL epitopes showed greater affinity binding to HLA-B 57*01, HLA-B*51:01 and HLA-B 27*02 molecules. The population coverage with the rate of >70% coverage in the Persian population supports this truncated form as an appropriate candidate against HIV-I virus. Conclusion: The predicted fusion protein, p24-AAY-Nef in a truncated form with a high rate of T cell epitopes and high conservancy rate among different clades, provides a helpful model for developing a therapeutic vaccine candidate against HIV-1.

[1]  J. Morlieras,et al.  Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates , 2018, npj Vaccines.

[2]  J. Mullins,et al.  Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection , 2018, Human vaccines & immunotherapeutics.

[3]  Yong Gao,et al.  A heterogeneous human immunodeficiency virus-like particle (VLP) formulation produced by a novel vector system , 2018, npj Vaccines.

[4]  Y. He,et al.  Conservation in gene encoding Mycobacterium tuberculosis antigen Rv2660 and a high predicted population coverage of H56 multistage vaccine in South Africa. , 2017, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[5]  P. Marche,et al.  Tailoring nanostructured lipid carriers for the delivery of protein antigens: Physicochemical properties versus immunogenicity studies. , 2017, Biomaterials.

[6]  M. Mahmoudi,et al.  Frequencies of HLA-A, B and DRB1 alleles in a large normal population living in the city of Mashhad, Northeastern Iran , 2017, Iranian journal of basic medical sciences.

[7]  G. Fouda,et al.  Lessons learned from human HIV vaccine trials , 2017, Current opinion in HIV and AIDS.

[8]  W. Koff.  A shot at AIDS. , 2016, Current opinion in biotechnology.

[9]  A. Ebihara,et al.  In silico proposition to predict cluster of B- and T-cell epitopes for the usefulness of vaccine design from invasive, virulent and membrane associated proteins of C. jejuni , 2016, In Silico Pharmacology.

[10]  Subhash C. Basak,et al.  A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines , 2016, International journal of molecular sciences.

[11]  R. Rappuoli,et al.  Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design , 2016, The Journal of experimental medicine.

[12]  B. Walker,et al.  Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial , 2016, Journal of acquired immune deficiency syndromes.

[13]  Shabnam Shamriz,et al.  Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant , 2016, BMC Bioinformatics.

[14]  Terianne M. Wong,et al.  Use of computational and recombinant technologies for developing novel influenza vaccines , 2016, Expert review of vaccines.

[15]  M. Raška,et al.  Endotoxin-minimized HIV-1 p24 fused to murine hsp70 activates dendritic cells, facilitates endocytosis and p24-specific Th1 response in mice. , 2015, Immunology letters.

[16]  E. Freed,et al.  HIV-1 assembly, release and maturation , 2015, Nature Reviews Microbiology.

[17]  J. Dikeakos,et al.  HIV-1 Nef: a master manipulator of the membrane trafficking machinery mediating immune evasion. , 2015, Biochimica et biophysica acta.

[18]  Jiang Zhu,et al.  Computational tools for epitope vaccine design and evaluation. , 2015, Current opinion in virology.

[19]  J. Mullins,et al.  HIV-1 Conserved Elements p24CE DNA Vaccine Induces Humoral Immune Responses with Broad Epitope Recognition in Macaques , 2014, PloS one.

[20]  R. Novak,et al.  Trial, Error, and Breakthrough: A Review of HIV Vaccine Development , 2014 .

[21]  A. Jahangiri,et al.  Computational vaccinology and epitope vaccine design by immunoinformatics. , 2014, Acta microbiologica et immunologica Hungarica.

[22]  M. Idrees,et al.  De Novo modeling of Envelope 2 protein of HCV isolated from Pakistani patient and epitopes prediction for vaccine development , 2014, Journal of Translational Medicine.

[23]  J. Mullins,et al.  Impact of Mutations in Highly Conserved Amino Acids of the HIV-1 Gag-p24 and Env-gp120 Proteins on Viral Replication in Different Genetic Backgrounds , 2014, PloS one.

[24]  J. Corbeil,et al.  MHC-NP: predicting peptides naturally processed by the MHC. , 2013, Journal of immunological methods.

[25]  Koichiro Tamura,et al.  MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. , 2013, Molecular biology and evolution.

[26]  Rahul Kumar,et al.  In Silico Approach for Predicting Toxicity of Peptides and Proteins , 2013, PloS one.

[27]  D. Richman,et al.  Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs , 2013, The Lancet.

[28]  I. Toth,et al.  Modern Subunit Vaccines: Development, Components, and Research Opportunities , 2013, ChemMedChem.

[29]  B. Dai,et al.  PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[30]  J. Baeten,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[31]  O. Yang,et al.  Epitope targeting and viral inoculum are determinants of Nef-mediated immune evasion of HIV-1 from cytotoxic T lymphocytes. , 2012, Blood.

[32]  Y. Xiong,et al.  Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef , 2012, Nature Structural &Molecular Biology.

[33]  J. Garcia,et al.  Overlapping effector interfaces define the multiple functions of the HIV-1 Nef polyproline helix , 2012, Retrovirology.

[34]  B. Haynes,et al.  Lessons learned from HIV-1 vaccine trials: new priorities and directions , 2012, Nature Immunology.

[35]  F. Sabaghi,et al.  Allele Frequencies of HLA-A, B and DRB1 among People of Fars Ethnicity Living in Tehran , 2011 .

[36]  R. Bock,et al.  Immunogenicity of chloroplast-derived HIV-1 p24 and a p24-Nef fusion protein following subcutaneous and oral administration in mice. , 2011, Plant biotechnology journal.

[37]  Morten Nielsen,et al.  NetCTLpan: pan-specific MHC class I pathway epitope predictions , 2010, Immunogenetics.

[38]  Shixia Wang,et al.  Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120/p24 fusion protein vaccine expressing alpha-gal epitopes. , 2010, Vaccine.

[39]  C. Alving,et al.  Human Immunodeficiency Virus Type 1 Gag p24 Alters the Composition of Immunoproteasomes and Affects Antigen Presentation , 2009, Journal of Virology.

[40]  J. Garcia,et al.  HIV-1 Nef: at the crossroads , 2008, Retrovirology.

[41]  Yaoqi Zhou,et al.  Specific interactions for ab initio folding of protein terminal regions with secondary structures , 2008, Proteins.

[42]  David Heckerman,et al.  Broad and Gag-Biased HIV-1 Epitope Repertoires Are Associated with Lower Viral Loads , 2008, PloS one.

[43]  Michio Inoue,et al.  Human Immunodeficiency Virus Type 1 Gag Engages the Bro1 Domain of ALIX/AIP1 through the Nucleocapsid , 2007, Journal of Virology.

[44]  Wei Li,et al.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines , 2007, BMC Bioinformatics.

[45]  D. Flower,et al.  Identifying candidate subunit vaccines using an alignment-independent method based on principal amino acid properties. , 2007, Vaccine.

[46]  Irini A. Doytchinova,et al.  BMC Bioinformatics BioMed Central Methodology article VaxiJen: a server for prediction of protective antigens, tumour , 2007 .

[47]  Peter Clote,et al.  DiANNA: a web server for disulfide connectivity prediction , 2005, Nucleic Acids Res..

[48]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[49]  Ellis L. Reinherz,et al.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.

[50]  C. Hidaka,et al.  Endogenously expressed HIV-1 nef down-regulates antigen-presenting molecules, not only class I MHC but also CD1a, in immature dendritic cells. , 2004, Virology.

[51]  B. Chain,et al.  The functional consequences of delivery of HIV-1 Nef to dendritic cells using an adenoviral vector. , 2004, Vaccine.

[52]  A. McMichael,et al.  Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. , 2001, Immunity.

[53]  D. Trono,et al.  HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes , 2000, Nature Cell Biology.

[54]  J. Luban,et al.  Human Immunodeficiency Virus Type 1 Gag Polyprotein Multimerization Requires the Nucleocapsid Domain and RNA and Is Promoted by the Capsid-Dimer Interface and the Basic Region of Matrix Protein , 1999, Journal of Virology.

[55]  Yen-Liang Chen,et al.  Nef-Induced CD4 and Major Histocompatibility Complex Class I (MHC-I) Down-Regulation Are Governed by Distinct Determinants: N-Terminal Alpha Helix and Proline Repeat of Nef Selectively Regulate MHC-I Trafficking , 1999, Journal of Virology.

[56]  A. Rein,et al.  Importance of Basic Residues in the Nucleocapsid Sequence for Retrovirus Gag Assembly and Complementation Rescue , 1998, Journal of Virology.

[57]  S. Höglund,et al.  A Putative α-Helical Structure Which Overlaps the Capsid-p2 Boundary in the Human Immunodeficiency Virus Type 1 Gag Precursor Is Crucial for Viral Particle Assembly , 1998, Journal of Virology.

[58]  S. Goff,et al.  Amino acid substitutions in the CA protein of Moloney murine leukemia virus that block early events in infection. , 1996, Virology.

[59]  Christophe Geourjon,et al.  SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments , 1995, Comput. Appl. Biosci..

[60]  T. Yeates,et al.  Verification of protein structures: Patterns of nonbonded atomic interactions , 1993, Protein science : a publication of the Protein Society.

[61]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[62]  S. M. Sadat,et al.  From in-silico immunogenicity verification to in vitro expression of recombinant Core-NS3 fusion protein of HCV. , 2017, Bratislavske lekarske listy.

[63]  K. Collins,et al.  HIV immune evasion disruption of antigen presentation by the HIV Nef protein. , 2011, Advances in virus research.

[64]  R. Zabihollahi,et al.  HIV-1 Gag p24-Nef fusion peptide induces cellular and humoral immune response in a mouse model. , 2010, Acta virologica.

[65]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[66]  J. Garcia,et al.  Role of Nef in HIV-1 replication and pathogenesis. , 2007, Advances in pharmacology.

[67]  R D Appel,et al.  Protein identification and analysis tools in the ExPASy server. , 1999, Methods in molecular biology.

[68]  Geoffrey J. Barton,et al.  JPred : a consensus secondary structure prediction server , 1999 .

[69]  D. Eisenberg,et al.  A method to identify protein sequences that fold into a known three-dimensional structure. , 1991, Science.

[70]  C. Chuong,et al.  Article type Software , 2007 .